KyungDong Pharm home
Prescription Medicines

Cadilan Tab.

Product Category
α/β receptor blocking antihypertensive agent
Active Ingredients
carvedilol
Appearance
white round tablet
Reimbursement Code
648101760
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: carvedilol (KP) ---------- 25mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, refined white sugar, colloidal silicon oxide, crospovidone, povidone

2. Efficacy/Effectiveness
1. Essential hypertension
2. Chronic stable angina
3. Congestive heart failure
Adjunctive treatment when administering diuretics, digitalis preparations, ACE inhibitors, and other vasodilators

3. Usage/Dosage
Do not increase the dose or stop taking it without a doctor's instructions.
1. Essential hypertension
1) Adult
(1) For the first two days, 12.5 mg of carvedilol is administered orally once a day, and then 25 mg is administered orally once a day.
(2) Usually, 25 mg is administered orally once a day for 2 weeks. If the dosage needs to be increased, increase 25 mg once to twice a day. The maximum dose per time is 25 mg, and the maximum daily dose is 50 mg.
2) Elderly people
For some elderly people, administration of 12.5 mg once a day may provide sufficient effect. However, if the effect is not sufficient after 2 weeks of administration, the dosage may be increased.

2. Chronic stable angina
1) For the first two days, take this drug orally at 12.5 mg twice a day, and then take 25 mg twice a day.
2) Typically, 25 mg is administered twice a day for 2 weeks. If the dosage needs to be increased (excluding the elderly), the dosage can be increased up to 50 mg twice a day.

3. Congestive heart failure
Before starting treatment with this drug, the existing standard treatment (conventional treatment for chronic heart failure with ACE inhibitors, diuretics, and usually digitalis preparations) must be stable. Additionally, fluid retention should be minimized before starting treatment with this drug.
1) In general, for initial treatment, 3.125 mg of this drug is administered orally twice a day for 2 weeks. If the patient tolerates this treatment well, increase the dose to 6.25 mg twice a day for 2 weeks.
After administration, increase the dose to 12.5 mg twice a day for 2 weeks, then increase the dose to 25 mg twice a day.
2) After taking each dose for at least 2 weeks, gradually increase the dose to a dose that the patient can tolerate.
3) The minimum effective dose is 6.25 mg twice a day, and the maximum dose is 25 mg twice a day for patients weighing less than 85 kg, and 50 mg twice a day for patients weighing more than 85 kg.
4) It is recommended to take it in the morning and evening with meals to control the absorption rate. When taken with a meal, it can slow the absorption rate and reduce the frequency of orthostatic hypotension.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its components
2) Patients with cardiogenic shock (circulatory failure may worsen)
3) Patients with particularly excited or blocked cardiac conduction, such as severe bradycardia (less than 50 beats/min), atrioventricular block (2nd or 3rd degree), sinoatrial block, sick-sinus syndrome, etc.
4) Patients with cor pulmonale (in patients with right heart failure caused by pulmonary hypertension, cardiac output may be suppressed and symptoms may worsen).
5) Patients with ketoacidosis or metabolic acidosis due to diabetes (inhibition of myocardial contractility may increase)
6) Patients with weakened myocardial strength, such as NYHA (New York Heart Association) Class Ⅳ patients with loss of cardiac function compensation mechanism, or patients with unstable heart failure
7) Patients with asthma, chronic obstructive pulmonary disease, respiratory diseases such as bronchospasm, or patients with a history of such diseases (since it can constrict bronchial muscles, it can cause and worsen symptoms. Deaths due to status asthmaticus have been reported with tablets.)
8) Patients with secondary hypertension
9) Patients with Prinzmetal angina (can cause chest pain)
10) Patients with acute pulmonary embolism
11) Patients with pheochromocytoma (there is concern that blood pressure may rise rapidly due to single administration of this drug.)
12) People taking MAO inhibitors (excluding MAO-B inhibitors)
13) Patients with severe hypotension with systolic blood pressure below 90 mmHg
14) Patients with severe liver function impairment
15) Pregnant women, women who may be pregnant, and lactating women
16) Patients with peripheral circulatory disorders (e.g. Raynaud's syndrome, intermittent claudication, etc.) (can inhibit peripheral vasodilatation and worsen blood flow disorder symptoms)
17) Patients with glottic edema
18) Patients with heart attacks accompanied by complications
19) Patients with significant fluid retention or overload requiring intravenous muscle inotropes
20) Patients with allergic rhinitis
21) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients (cases):
1) Diabetics
2) Patients with a history of severe hypersensitivity reactions or patients receiving treatment to reduce sensitivity (hyposensitization therapy) (beta-blockers increase sensitivity and hypersensitivity to allergens)
3) Patients with a history of psoriasis caused by beta-blockers or patients with a family history of such disease
4) Patients with low blood pressure (systolic blood pressure less than 100 mmHg), widespread vascular disease due to ischemic heart disease, or renal dysfunction (reversible renal dysfunction may occur when taking this drug).
5) Patients with unstable angina (since there is little clinical experience, caution should be exercised when administering this drug to patients showing these signs or symptoms.)
6) Patients with chronic congestive heart failure (When increasing the dose of this drug in patients with congestive heart failure, heart failure may worsen or fluid retention may occur.)
7) Patients with severe renal impairment (increased blood concentration of this drug has been reported)
8) Patients with first-degree atrioventricular block (atrioventricular conduction time may be prolonged and symptoms may worsen)
9) Patients with mild to moderate bradycardia
10) Patients taking beta blockers in the form of eye drops
11) Elderly people
12) Patients who tend to lower blood pressure when changing posture
13) Patients with acute inflammatory heart disease, heart valve or cardiovascular changes
14) Patients taking combined use of α1-receptor antagonists or α2-receptor agonists
15) Patients with salt or water deficiency (e.g., taking high doses of diuretics)
16) Patients receiving cardiac glycosides simultaneously
17) Patients concurrently taking non-dihydropyridine calcium channel blockers or antiarrhythmic drugs such as verapamil and diltiazem
18) Fasting patients
19) Patients with hyperthyroidism
20) Patients using contact lenses
21) Children and adolescents under 18 years of age
22) Patients with hemodynamic instability among patients with acute myocardial infarction
23) Hypertensive patients with coronary heart disease

3. Adverse reactions
1) Central nervous system: Dizziness, headache, fatigue, and rarely weakness may occur, but these symptoms are usually mild and occur especially in the early stages of treatment. In rare cases, hallucinations, confusion, depression, sleep disorders, nightmares, and psychosis may occur.
2) Cardiovascular system
(1) Since serious adverse reactions such as severe bradycardia, shock, complete atrioventricular block, heart failure (including acute), and cardiac arrest may occur, cardiac function tests should be performed regularly, and if such symptoms appear, appropriate measures, such as reducing the dose or discontinuing the dose, should be taken.
(2) Occasionally, especially when taking this drug for the first time or increasing the dosage, or when standing up suddenly, blood pressure may drop significantly along with symptoms such as dizziness and blurry vision, and in rare cases, loss of consciousness may occur.
(3) Sometimes the pulse rate may decrease, and in rare cases, cold extremities may appear. These symptoms may worsen in patients with intermittent claudication, Raynaud's disease, angina, and edema.
(4) Patients with heart failure may experience dizziness, sometimes edema of various lesions and sizes, rarely (especially when the dose is increased) atrioventricular block, and worsening of heart failure.
(5) Sinus palpitations may occur in predisposed patients (e.g., elderly patients or patients with pre-existing bradycardia, sinus node dysfunction, or atrioventricular block).
3) Kidney: People with systemic vascular disorders or impaired renal function may experience worsening renal function or, in rare cases, renal failure.
4) Respiratory system: Resistance of the respiratory tract may increase.
5) Digestive system: Occasionally nausea, diarrhea, abdominal pain, vomiting, and in rare cases constipation may occur.
6) Skin: Hives, itching, lichen planus-like reaction, hyperhidrosis, etc. have been reported, and in rare cases, allergic rash may appear. Drugs with beta-blocking properties may cause psoriasis vulgaris, worsen the symptoms of the disease, or cause a psoriatic rash.
7) Blood system: Changes in liver function indicators such as serum transaminases, thrombocytopenia, and leukopenia have been rarely reported.
8) Endocrine system: Due to the nature of beta blockers, latent diabetes may develop, symptoms may worsen, blood sugar control may be suppressed, and hypoglycemia or hyperfunction of the thyroid gland (high heart rate, etc.) may be concealed. Patients with heart failure may experience high blood sugar, weight gain, and increased blood cholesterol levels (if they already have diabetes).
9) Circulatory system: bradycardia, hypotension, shortness of breath, and dizziness may occur (less than 0.1 to 5%), and in rare cases, hypertension may occur in patients with angina pectoris.
10) Liver: Liver dysfunction and jaundice accompanied by elevations of AST, ALT, and γ-GTP may occur. If symptoms of liver dysfunction (e.g. dark urine color, persistent loss of appetite, jaundice, pressure pain in the upper right, unexplained flu symptoms, etc.) appear, the patient should be carefully examined and use of this medicine should be discontinued if liver damage or jaundice is evident.
11) Others: Occasionally, pain in the extremities, decreased tearing, rare sensory disturbances (paresthesia, paresthesia), visual impairment, eye irritation, dry mouth, urinary difficulties (including urinary incontinence), sexual dysfunction, and allergic reactions may occur.
12) Domestic post-marketing surveillance results (congestive heart failure: 721 cases, chronic stable angina: 661 cases) Reported adverse reactions: All of the following adverse reactions occurred rarely, less than 0.1%, and it is unclear whether they are related to this drug.
(1) Congestive heart failure: cerebrovascular disorder, increased sputum, tachycardia, hyperglycemia, flushing, leukocytosis, hematuria
(2) Chronic stable angina: myocardial infarction, hyperkalemia

4. General precautions
1) During long-term administration, cardiac function tests (pulse, blood pressure, electrocardiogram, X-ray, etc.) are performed regularly. In particular, if bradycardia or hypotension occurs, reduce the dose or discontinue the dose. Also, pay attention to liver function, renal function, and blood status.
2) There have been reports of angina patients receiving beta-blockers (propranolol hydrochloride) whose symptoms worsened or myocardial infarction occurred when the medication was suddenly discontinued. Therefore, if medication withdrawal is necessary, slowly reduce the dose and observe thoroughly. Do not stop taking it without a doctor's instructions, and be especially careful in elderly people.
3) The blood pressure lowering effect may be amplified when first administered or when the dose is increased in patients with salt and/or body fluid deficiency (such as those receiving high doses of diuretics), the elderly over 70 years of age, and patients with low blood pressure with an initial systolic blood pressure of 100 mmHg or less, so observe carefully for up to 2 hours after administration.
4) When co-administration with clonidine must be discontinued, the dose of clonidine should be gradually reduced for several days after discontinuing this drug. Additionally, when changing from clonidine to this drug, it is recommended to start taking this drug a few days after stopping clonidine.
5) Administration should not be stopped abruptly (especially in patients with chronic stable angina or ischemic heart disease, the frequency and pain of angina attacks may worsen, and in rare cases, myocardial infarction or temporary increase in blood pressure may occur), but gradually discontinue over 2 weeks. Administer antianginal drugs when necessary to prevent worsening of angina.
6) If the heart rate falls below 55 beats per minute, the dose should be gradually reduced. If the heart rate falls below 50 beats per minute, treatment with this drug should be discontinued. If there is first-degree atrioventricular block, the drug should be administered with caution.
7) Like other beta blockers, it can mask symptoms of hyperthyroidism. In addition, if patients with hyperthyroidism suddenly stop taking the drug, their symptoms may worsen (e.g., worsening of hyperthyroid symptoms, thyrotoxic attack, etc.), so if discontinuation is necessary, the patient's condition must be fully observed and the dosage should be reduced gradually over 1 to 2 weeks. Additionally, patients are instructed to reduce physical activity when reducing weight.
8) Those who use contact lenses may experience reduced tearing.
9) As a result of a study on Koreans, the body kinetics of carvedilol was observed to be higher in patients with poor metabolizers than in CYP2D6 extensive metabolizers, so it should be used with caution in patients with CYP2D6 poor metabolizers.
10) It is advisable not to administer for 48 hours before surgery. Extreme caution must be exercised when administering anesthetics that reduce myocardial function.
11) During the dose titration phase of this drug, a decrease in myocardial contractility may lead to worsening of heart failure.
12) After taking the first dose of this drug, during the first week of treatment, and when increasing the dose, it is recommended to periodically check blood pressure and electrocardiogram. When the effective dose is reached, periodic tests of kidney function are also recommended. To reduce syncope or excessive lowering of blood pressure, it is recommended that this medication be taken with food, starting at a low dose and gradually increasing the dose. At the start of treatment, patients should not drive or perform hazardous tasks.
13) This drug contains active ingredients that can cause positive reactions in tests conducted during doping tests.
14) In the case of heart failure, if treatment with this drug is discontinued for more than 2 weeks, the recommended therapeutic dose is 3.125 mg twice a day (8 mg once a day for extended-release capsules), and it is recommended to increase the dose in accordance with the above dose increase.
15) When this drug is administered to diabetic patients, the rapid drop in blood sugar may be hidden or less pronounced, and blood sugar control may become difficult. Therefore, blood sugar levels should be monitored regularly when starting the drug or when adjusting blood sugar lowering therapy.
16) Since reversible renal dysfunction may occur when taking this drug, renal function should be monitored when starting or increasing the dose. If renal function worsens, reduce the dose or stop taking this drug.
17) When increasing the dose of this drug in patients with congestive heart failure, heart failure may worsen or fluid retention may occur. If these symptoms occur, the diuretic dose should be adjusted and the dose should not be increased until clinical stability. Sometimes it is necessary to reduce or stop taking this medication.
18) Depending on the patient, dizziness and drowsiness may occur and it may affect the state of awakening, so be careful when driving or operating machinery. Be especially careful when starting this medication, changing the dosage, changing treatment, or taking alcohol.
19) In very rare cases, severe skin adverse reactions such as Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome have been reported during administration of this drug. Patients who experience severe skin adverse reactions that may be attributable to this drug should permanently discontinue taking this drug.

5. Interaction
1) Since this drug is both a substrate and an inhibitor of P-glycoprotein, the bioavailability of drugs transported through P-glycoprotein may increase when this drug is administered together. And the bioavailability of this drug may vary depending on the inducer or inhibitor of P-glycoprotein.
2) Inhibitors and inducers of CYP2D6 and CYP2C9 may stereoselectively change the metabolism of this drug, increasing or decreasing the plasma concentration of R- and S-isomers.
3) The effect of other drugs with a blood pressure lowering effect or side effects of drugs with a blood pressure lowering effect (e.g., sedatives such as barbiturates, phenothiazines, antidepressants, vasodilators, alcohol, etc.) may be increased, and when used in combination with reserpine, guanethidine, methyldopa, clonidine, guanfacine, MAO inhibitors, etc., the heart rate may further decrease and severe bradycardia may occur.
4) When administered orally in combination with diltiazem, cardiac conduction disorders (rarely with hemodynamic damage) have been reported. When administered in combination with calcium channel blockers such as verapamil and diltiazem and arrhythmia treatments such as amiodarone, the heart rate may slow, excessive cardiac function may be suppressed, and the risk of atrioventricular conduction disorder may increase. Therefore, electrocardiogram and blood pressure should be carefully monitored, and intravenous injection should not be administered concurrently.
5) There have been reports that the blood concentration of digoxin increased by approximately 15% (maximum 60%) when administered in combination with digoxin to patients with hypertension. Therefore, the concentration of digoxin should be monitored when starting and stopping the drug and adjusting the dose. Additionally, when used in combination with cardiac glycosides, heart rate may decrease significantly and atrioventricular conduction may be delayed.
6) Cyclooxygenase inhibitors (e.g. acetylsalicylic acid, corticosteroids, etc.) may reduce the blood pressure lowering effect of this drug.
7) It can enhance the effect of insulin or oral hypoglycemic agents, and can hide symptoms of hypoglycemia (especially increased heart rate). Patients taking insulin or oral hypoglycemic agents should monitor their blood sugar levels regularly.
8) Substances that induce mixed function oxidase (e.g., rifampicin, etc.) decrease the plasma concentration of this drug, and inhibitors of this enzyme (e.g., cimetidine, etc.) may increase the plasma concentration of this drug by lowering hepatic metabolism.
9) When this drug is taken together with anesthetics or narcotics, the contraction force-reducing effect and blood pressure-lowering effect may increase, so vital signs must be carefully monitored during anesthesia.
10) In two clinical trials conducted on kidney transplant patients and heart transplant patients taking oral cyclosporine, the plasma concentration of cyclosporine increased after starting to take this drug. This drug has been shown to increase absorption of cyclosporine by inhibiting P-glycoprotein activity in the intestine. To maintain the therapeutic concentration of cyclosporine, it is necessary to reduce the dose of cyclosporine by an average of 10 to 20%. Because inter-individual variation in cyclosporine concentrations is large, cyclosporine concentrations should be monitored after starting treatment with this drug.
11) In a clinical trial involving 12 healthy subjects, the administration of rifampicin decreased the plasma concentration of this drug mainly through the induction of P-glycoprotein, thereby reducing the intestinal absorption of this drug and reducing its antihypertensive effect.
12) Amiodarone, an inhibitor of CYP2C9, increased the plasma concentration of the S-isomer of carvedilol by more than two-fold. Therefore, when co-administered with CYP2C9 inhibitors such as amiodarone, there is a risk of increased beta-blocker effect, so signs such as bradycardia or cardiac arrest should be observed.
13) Patients taking beta-blockers and drugs that deplete catecholamines (e.g., reserpine, MAO inhibitors) should be carefully observed for symptoms of hypotension and/or severe bradycardia.
14) When non-steroidal anti-inflammatory drugs (NSAIDs) and beta blockers are administered together, blood pressure may increase and may not be well controlled.
15) Cardiac non-selective beta blockers interfere with the bronchodilating effect of beta-agonist bronchodilators, so asthma patients taking bronchodilators should be carefully monitored.
16) There is a risk of excessive bradycardia when used in combination with anticholinesterase.
17) When used in combination with baclofen, the blood pressure lowering effect increases and there is a particular risk of orthostatic hypotension.
18) When used in combination with tricyclic antidepressants and neuroleptics, there is a risk of vasodilation and increased risk of orthostatic hypotension.
19) Tacrolimus is a substrate of P-glycoprotein and CYP3A4, so its pharmacokinetics may be affected by interactions with this drug.
20) Since alcohol has an acute blood pressure lowering effect, concurrent intake with this drug may increase the blood pressure lowering effect. Alcohol may increase the solubility of this drug, which may affect the rate and/or amount of intestinal absorption. Additionally, this drug is partially metabolized by the CYP2E1 enzyme, which is induced and inhibited by alcohol.
21) When used in combination with grapefruit juice, the blood concentration of this drug may slightly increase, so avoid concurrent intake until a stable dose-response relationship is established.

6. Administration to pregnant and lactating women
1) Do not administer to pregnant women or women who may be pregnant, as safety has not been established. Beta-blockers block placental perfusion, which may result in intrauterine death of the fetus, birth defects, or premature birth. It can also cause hypoglycemia, bradycardia, respiratory depression, and high fever in newborns. Additionally, acute pulmonary edema or heart failure requiring hospitalization may occur.
2) Since the metabolites of this drug pass into breast milk, do not breast-feed while taking this drug. This drug should not be administered to breastfeeding women.

7. Administration to children
Safety and efficacy in children and adolescents under 18 years of age have not been established. Cases of severe hypoglycemia and death have been reported in infants and children with severe heart failure due to administration of this drug.

8. Administration to elderly people
This drug is mainly metabolized in the liver, and elevated blood levels have been reported in patients with severe hepatic impairment. In general, elderly people often have reduced liver function, so there is a risk that blood levels may increase, and excessive lowering of blood pressure in elderly people is undesirable due to the risk of cerebral infarction, etc. Therefore, when administering to elderly patients, it is recommended to administer cautiously while carefully observing the patient's condition, such as starting administration at a low dose.

9. Treatment in case of overdose
Overdosage may cause a marked drop in blood pressure, slowed heart rate, myocardial weakness, cardiogenic shock, sinus arrest, cardiac arrest, difficulty breathing, bronchospasm, vomiting, impaired consciousness, and generalized seizures. If these symptoms occur, immediately report them to your doctor and take appropriate action. In case of overdose, have the patient lie down and remove the drug by gastric lavage or inducing vomiting. This drug is difficult to remove by hemodialysis.
In case of severe poisoning with shock symptoms, supportive treatment with antidote should be continued for a sufficiently long time, as the elimination half-life of this drug is quite long. The duration of antidote treatment depends on the severity of the overdose. Supportive treatment should be continued until the patient recovers.

10. Application precautions
1) This drug is administered to patients with a left ventricular ejection fraction of 45% or less, a resting heart rate of 65 beats per minute or more, and basic heart failure treatment that has been stable for at least 4 weeks (there is no change in NYHA class or basic treatment and no hospitalization due to worsening symptoms).
2) Whenever the dose is increased, the doctor must check for worsening of the patient's heart failure symptoms and adverse reactions (lower blood pressure, dizziness) due to vasodilation, and conduct regular checkups (heart function, weight, blood pressure, heart rate, etc.). If heart failure symptoms temporarily worsen or fluid retention occurs, treatment is performed by increasing the dose of the diuretic, and sometimes the dose of this drug is reduced or the medication is temporarily discontinued. If you start taking the medication again after taking a break for more than 2 weeks, start with the initial dose (3.125 mg twice a day (8 mg once a day for extended-release capsules)) and follow the ‘Dosage and Instructions’.

11. Storage and handling precautions
1) Since discoloration occurs when exposed to light, store in a light-proof, airtight container.
2) Be careful to keep it out of reach of children.
3) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)

6. Packaging unit
100 tablets (10 tablets/Alu-Alu

7. Expiration date
36 months from date of manufacture

Product Updates

Total 5items

No.Product NameDetailsDate of ChangeDownload
5Cadilan Tab.Precautions for use2023.07.03PDFCadillan tablet (carvedilol) change plan + change comparison table.pdf
4Cadilan Tab.Cadillan tablets (precautions for use)2013.01.30HWPCadillanjeong.hwp
3Cadilan Tab.Cadillan tablets (efficacy, dosage, directions for use...2012.12.31HWPCadillan Pavilion_Permit change order.hwp
2Cadilan Tab.Cadillan tablets (precautions for use)2009.10.07HWPCadillan tablet (precautions for use) change (2009.10.12).hwp
1Cadilan Tab.Cadillan tablets (precautions for use)2007.05.03HWPChange in Cadillan tablets (precautions for use) (2007.05.04).hwp